Related Experiment Video
Updated: Jun 10, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
[Depression in Parkinson's disease--Part 2: Therapy and management]
A Storch1, C Schneider, G Ebersbach
1Die Institutsangaben sind am Ende des Beitrags gelistet. Alexander.Storch@neuro.med.tu-dresden.de
Fortschritte Der Neurologie-Psychiatrie
|August 10, 2010
Summary
Effective treatments for depressive symptoms are available, but research on managing depression in Parkinson's disease patients is limited. This survey reviews current therapeutic strategies and offers guidance for better patient care.
Area of Science:
- Neurology
- Psychiatry
Context:
- Parkinson's disease (PD) frequently co-occurs with depression, significantly impacting patient quality of life.
- Despite available treatments for depressive symptoms, specific evidence for PD patients is scarce.
Purpose:
- To provide a comprehensive overview of current treatment options for depression in Parkinson's disease patients.
- To highlight the need for more controlled studies in this specific patient population.
Summary:
- Reviews pharmacological, somatic, and psychological treatment modalities for depression in PD.
- Emphasizes the critical role of managing depressive symptoms for PD patients' well-being.
- Notes that over half of PD patients with depression do not receive adequate treatment.
Impact:
- Aims to improve the management of depressive symptoms in individuals with Parkinson's disease.
- Provides clinicians with evidence-based suggestions for treatment strategies.
- Highlights gaps in research and encourages further controlled studies.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...